KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.Ravindra Uppaluri, Douglas R. Adkins, William H. Westra et al.|Journal of Clinical Oncology|2019Cited by 51
MET Genetic Abnormalities Unreliable for Patient Selection for Therapeutic Intervention in Oropharyngeal Squamous Cell CarcinomaLudovic Lacroix, Stéphane Temam|PLoS ONE|2014Cited by 17